Sensorion raises $16m for gene therapies to treat deafness
Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.
Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.
What's Your Reaction?
